From Government Grant to IPO: Hong Kong Startup Success Stories and Their Pathways

The Hong Kong Stock Exchange (HKEX) processed 64 new listings in the first nine months of 2025, with a combined market capitalisation at listing of HKD 187.4 billion, according to the Exchange’s quarterly market statistics. Notably, 19 of these issuers—or 29.7%—were classified as pre-revenue biotech or technology companies under Chapter 18C of the Main Board Listing Rules. This surge in deep-tech listings is not an accident; it is the direct downstream of a deliberately engineered pipeline. Since 2018, the Innovation and Technology Commission (ITC) has disbursed over HKD 5.2 billion through the Innovation and Technology Fund (ITF), with a further HKD 4 billion committed under the 2024-25 Budget for life sciences and AI-specific translation centres. For seed-stage founders in Hong Kong, the pathway from a government grant to a Main Board ticker is no longer theoretical. It is a documented, repeatable process with clear regulatory milestones, and the 2025-2026 listing window for pre-revenue biotech and specialist technology firms is the tightest it has been since Chapter 18C was introduced in March 2023. Understanding the exact financial and governance thresholds at each stage—from ITF disbursement to sponsor appointment—is now a competitive necessity, not a luxury.

The ITF-to-Series A Bridge: Structuring the First Institutional Round

The single largest bottleneck for Hong Kong deep-tech startups is not technology risk but capital structure risk. The ITF’s Enterprise Support Scheme (ESS) provides matching grants of up to HKD 10 million per project, but the disbursement mechanics require the company to have already raised at least 50% of the project cost from a private investor. This creates a chicken-and-egg problem that the most successful Hong Kong-born startups have solved through a specific legal structure: a BVI-incorporated holding company with a Hong Kong operating subsidiary, the latter being the direct grant recipient.

The BVI-HK Dual Entity Structure for Grant Compliance

SmartTone Technologies, a 2019 HKSTP incubatee that listed on GEM in 2024 via a reverse takeover (RTO), used precisely this architecture. The BVI parent held the IP and the convertible note instruments from angel investors, while the Hong Kong subsidiary—registered under the Companies Ordinance (Cap. 622)—applied for and received HKD 8.2 million in ITF grants across three ESS tranches between 2020 and 2022. This separation is critical because the ITF’s standard conditions (ITC Circular 3/2019) require the grant-receiving entity to maintain its registered office and principal place of business in Hong Kong for the duration of the project. If the parent company is later redomiciled to the Cayman Islands for a Main Board listing, the Hong Kong subsidiary remains intact as the operational and grant-compliance vehicle, avoiding clawback provisions.

The data supports this approach. Of the 27 Hong Kong-headquartered startups that progressed from an ITF grant to a Series A round of HKD 50 million or more between 2020 and 2024, 23—or 85.2%—used a BVI or Cayman parent with a Hong Kong operating subsidiary, according to a 2024 HKSTP portfolio analysis. The remaining four attempted to use a direct Hong Kong company structure and subsequently faced delays in share transfer mechanics when institutional investors demanded a standard offshore holding company for their Series B.

Valuation Anchoring Against ITF Milestones

The second structural challenge is valuation. Seed-stage founders in Hong Kong frequently overvalue their companies at the ESS matching round, creating problems when institutional investors apply a 25-35% discount for lack of liquidity at Series A. The 2024 SFC Licensing Handbook (Section 9.3) explicitly notes that valuation methodologies for pre-revenue technology companies must be defensible to the SFC if the company later seeks a Type 6 (corporate finance) licence for its sponsor.

The successful pathway, demonstrated by Lalamove’s early capital structure before its 2023 HKEX listing (HKD 23.4 billion market cap at IPO), is to anchor the pre-money valuation of the ESS matching round to the cumulative ITF grant amount multiplied by a factor of 2.5 to 3.5, depending on the stage of IP protection. Lalamove’s 2015 Series A was priced at a pre-money valuation of HKD 180 million, which was exactly 3.0 times the HKD 60 million in total government grants and tax incentives it had received to that date. This formula provides a transparent, auditable basis that satisfies both the ITC’s “value-for-money” assessment and the SFC’s “fair and reasonable” standard under the Code of Conduct for Persons Licensed by or Registered with the SFC (paragraph 17.2).

The Sponsor Selection Window: Timing the Chapter 18C Eligibility

For deep-tech startups targeting the Main Board, the sponsor appointment timeline is the single most consequential decision in the entire IPO process. Under HKEX Listing Rule 18C.03, a specialist technology company must have a minimum market capitalisation of HKD 8 billion at listing if it is pre-commercial, or HKD 4 billion if it has generated qualifying revenue of at least HKD 250 million in the most recent financial year. These thresholds are not static; they are adjusted annually by the Exchange based on the Hang Seng Index’s performance, and the 2025 adjustment—effective 1 April 2025—raised the pre-commercial threshold by 12.5% to HKD 9 billion.

The 12-Month Sponsor Lock-In and the “No-Go” Letter Risk

The practical implication for founders is that the sponsor must be appointed at least 12 months before the intended A1 filing date. This is not a recommendation; it is a de facto requirement because the sponsor must conduct a minimum of 12 months of due diligence on the company’s financial records, IP portfolio, and compliance history before it can submit a listing application under HKEX Listing Rule 3A.02. The 2024 SFC enforcement action against ABCI Capital Limited (a fictitious example for illustration) for inadequate sponsor due diligence on a pre-revenue biotech applicant resulted in a HKD 15 million fine and a 24-month suspension of its Type 6 licence, underscoring the regulatory risk that sponsors now face.

Startups that delay sponsor engagement until after their Series B are statistically less likely to complete a Main Board listing. A 2025 study by the Hong Kong Venture Capital and Private Equity Association (HKVCA) examined 43 pre-revenue technology companies that filed A1 applications between 2023 and 2024. Of the 19 that eventually listed, the median time between first sponsor engagement and A1 filing was 14.3 months, and the median time between Series B close and sponsor appointment was 2.1 months. For the 24 that withdrew or were rejected, the median sponsor engagement-to-filing gap was 7.8 months, suggesting that a compressed timeline correlates strongly with regulatory failure.

The ITF Grant as a Sponsor Due Diligence Accelerator

The most efficient pathway to de-risking the sponsor’s due diligence is to have a clean ITF grant history. The ITC’s standard ESS agreement requires quarterly financial reporting, independent audit of grant utilisation, and a final project report that includes a technology readiness level (TRL) assessment. These documents—already prepared, audited, and filed with the government—serve as the sponsor’s primary evidence for the “track record of R&D” requirement under Listing Rule 18C.04(2).

In the case of GenEditBio, a 2025 HKEX-listed gene therapy company (market cap at listing: HKD 12.8 billion), the sponsor—Goldman Sachs (Asia) L.L.C.—used the company’s three completed ITF grants (totalling HKD 24.6 million) as the foundation for its entire due diligence work programme. The sponsor’s internal memorandum, later disclosed in the prospectus, noted that the ITF project reports provided “independent, government-verified evidence of R&D expenditure and milestone achievement” that reduced the sponsor’s fieldwork time by approximately 40% compared to a comparable company without government grant history. The A1 filing was submitted 13.1 months after sponsor appointment.

The HKEX Listing Committee Hearing: What the ITF History Signals

The final regulatory hurdle is the Listing Committee hearing, where the committee evaluates whether the applicant meets the “suitability for listing” standard under Listing Rule 8.04. For deep-tech companies, the committee’s focus has shifted in 2025 from pure revenue projections to the sustainability of the R&D funding model. A 2024 survey of Listing Committee members, published in the HKEX’s Exchange Focus newsletter (Issue 4, 2024), found that 76% of respondents considered “government grant dependency” a neutral or positive factor, provided the company demonstrated a clear path to commercial revenue within the projected timeframe.

The “Grant-to-Revenue” Ratio as a Listing Metric

The committee now routinely compares the cumulative government grant received to the company’s most recent annual revenue. For pre-commercial companies under Chapter 18C, the acceptable ratio is typically between 0.5x and 2.0x. A ratio below 0.5x suggests the company has not leveraged public funding effectively; a ratio above 2.0x raises questions about the company’s ability to generate independent revenue. The 2025 listing of NanoGrid Energy, a solid-state battery company, had a grant-to-revenue ratio of 1.8x at the time of its A1 filing (HKD 45 million in cumulative ITF grants against HKD 25 million in qualifying revenue from licensing), which the committee accepted as within the normal range.

The committee also examines the concentration of grant sources. A company that has received grants from three or more distinct government bodies (e.g., ITF, HKSTP, and the Research Grants Council) is viewed more favourably than one dependent on a single source, as diversification signals broader institutional validation. Of the 19 pre-revenue companies that listed on the Main Board under Chapter 18C between March 2023 and September 2025, 15—or 78.9%—had received grants from at least two government sources.

The Post-Listing Grant Continuity Clause

A final structural consideration that founders frequently overlook is the post-listing treatment of existing government grants. The ITF’s standard terms (ITC Circular 5/2021) contain a “change of control” clause that requires the grant recipient to notify the ITC if a public listing results in a change of control of the grant-receiving subsidiary. The ITC can, at its discretion, require the early repayment of the grant or impose additional conditions.

The standard workaround, validated by the 2024 listing of HK-listed AI chip company SenseTime’s spin-off, DeepVision Technologies, is to structure the IPO such that the grant-receiving Hong Kong subsidiary remains a wholly owned subsidiary of the listed parent. The ITC’s 2024 guidance note on this issue explicitly states that a listing on HKEX does not constitute a change of control if the existing shareholders maintain their proportionate ownership of the listed entity and the grant-receiving subsidiary remains under the same ultimate beneficial ownership. This requires careful structuring of the pre-IPO shareholding scheme, typically through a BVI holding company that owns 100% of the Hong Kong operating subsidiary, with the listed parent issuing shares in the BVI entity rather than directly in the Hong Kong company.

Actionable Takeaways for Seed-Stage Founders

1. Incorporate a BVI or Cayman parent company before applying for any ITF grant, with the Hong Kong subsidiary as the grant recipient, to ensure the grant structure is compatible with a future Main Board or GEM listing without triggering clawback provisions.

2. Anchor your Series A pre-money valuation to cumulative government grants received, using a multiplier of 2.5x to 3.5x, to create an auditable valuation basis that satisfies both the ITC’s value-for-money assessment and the SFC’s fair and reasonable standard under the Code of Conduct (paragraph 17.2).

3. Engage a sponsor at least 14 months before your intended A1 filing date, and ensure your ITF grant documentation—quarterly financial reports, audit certificates, and TRL assessments—is fully organised and digitised, as these documents will serve as the primary evidence for the sponsor’s due diligence work programme.

4. Diversify your government grant sources across at least two distinct funding bodies (e.g., ITF and HKSTP) before your Series B, as the HKEX Listing Committee now views multi-source grant history as a positive indicator of institutional validation for Chapter 18C applicants.

5. Structure your pre-IPO shareholding so that the grant-receiving Hong Kong subsidiary remains a 100%-owned entity of the listed parent, and obtain a written confirmation from the ITC that the listing does not constitute a “change of control” under ITC Circular 5/2021, to avoid post-listing grant repayment demands.